Share This Page
Patent: 7,001,602
✉ Email this page to a colleague
Summary for Patent: 7,001,602
| Title: | Use of botulinum toxin therapy for urinary incontinence and related disorders | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Schmidt; Richard A. (Arvada, CO) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | The Regents of the University of Colorado (Boulder, CO) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | 10/685,995 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | United States Patent 7,001,602: Claims, Expiration, FDA Status, and Patent Landscape for Botulinum-Toxin Treatment of Urinary IncontinenceUnited States Patent 7,001,602 covered methods of treating urinary incontinence by administering botulinum toxin, including botulinum toxin type A, to a patient. Its central claims were broad method-of-treatment claims, while dependent claims narrowed the patient population, formulation, injection site, incontinence type, and therapeutic result. The patent’s nominal U.S. term has expired. It therefore does not currently block Botox, other botulinum-toxin products, generic drug products, or competing biologics from practicing the claimed urinary-incontinence treatment method. The patent remains commercially important as an early foundation for intradetrusor botulinum-toxin therapy, but it has no remaining patent-based exclusivity. What does U.S. Patent 7,001,602 cover?Patent 7,001,602 covers administering botulinum toxin to a patient with urinary incontinence to treat the condition. The patent includes both broad and narrowed claims.
The practical center of gravity is claims 1, 4, 7, 8, 9, 10, and 11. Those claims map most closely to contemporary intradetrusor Botox treatment for overactive bladder and neurogenic detrusor overactivity. How strong were the independent claims of Patent 7,001,602?Claims 1 and 11 were commercially broad but technically vulnerable to prior-art and enablement challenges. Claim 1 requires four core elements:
Claim 11 narrows the claim to a human patient and botulinum toxin type A. It is narrower than claim 1 but more closely aligned with the approved Botox product. The claims do not specify:
That breadth helped the patent reach multiple possible clinical implementations. It also created potential validity pressure. Earlier literature concerning botulinum toxin, neurogenic bladder, detrusor spasticity, and injection into the urinary tract could have been relevant to novelty, obviousness, written-description, or enablement defenses. What are the principal claim-construction issues?The phrase “treating urinary incontinence” is functional and potentially broad. A claimant would need to show that the accused administration was directed to a patient with urinary incontinence and that treatment occurred. A mere prescription or possession of botulinum toxin would not itself practice the method. Claim 7 is materially narrower because it requires injection into the urinary tract or bladder and identifies acceptable liquid, emulsion, suspension, or solution formulations. A product used through a different route would present a stronger noninfringement position under that claim, although claims 1, 4, 8, 9, 10, or 11 could still have been relevant during the patent term. Claims 9 and 10 use result-based limitations. Increased bladder capacity and reduced bladder spasticity may require clinical or scientific evidence linking the administration to the claimed result. These claims would not necessarily cover every treatment that reduces leakage if the required physiological result was absent. When did Patent 7,001,602 expire?The patent’s enforceable U.S. term has ended. Public patent records identify a nominal term ending in 2021, subject to the precise patent-term calculation recorded by the USPTO. The patent is therefore not a current barrier to market entry.
Expiration eliminates the patent owner’s ability to obtain prospective infringement relief based on future practice of the claims. It does not erase historical infringement exposure during the enforceable term, subject to the statute of limitations and other defenses. What is the FDA and Orange Book status of Patent 7,001,602?Patent 7,001,602 is not a current Orange Book barrier for Botox urinary-incontinence treatment. Botox is regulated as a biologic under Biologics License Application No. 103000, rather than as a conventional small-molecule drug approved through an NDA. The Orange Book primarily lists patents for approved drug products submitted under the applicable drug-approval framework. Biologic exclusivity and biosimilar competition are addressed principally through the Public Health Service Act and the FDA’s Purple Book framework. FDA approved Botox for:
The approved dosing differs by indication. The FDA label identifies 100 Units for adult overactive bladder and 200 Units for detrusor overactivity associated with a neurologic condition, administered by cystoscopic injection into the detrusor muscle, with specified injection-site and safety requirements. These regulatory details are narrower than the patent’s broad formulation and administration language.[1] Does the patent create current FDA exclusivity?No. Patent 7,001,602 is expired and does not provide current FDA exclusivity. FDA approval of Botox for urinary indications remains commercially relevant, but approval is separate from patent exclusivity. A competing botulinum-toxin product may require its own regulatory approval, clinical evidence, labeling, potency characterization, manufacturing controls, and pharmacovigilance system even though the expired patent no longer blocks the underlying treatment method. Were there Paragraph IV challenges to Patent 7,001,602?A traditional Paragraph IV challenge is not the principal pathway for competing Botox products because Botox is a biologic licensed under a BLA rather than a conventional small-molecule product approved under an NDA. A follow-on biologic applicant would generally proceed under the 351(k) biosimilar or interchangeable-biologic pathway. The relevant legal framework includes:
Because Patent 7,001,602 expired before current biosimilar competition could create a meaningful challenge around this claim set, it does not present an active Paragraph IV or BPCIA patent dispute. What formulations are protected by Patent 7,001,602?Claims 5 and 6 attempt to cover a wide range of pharmaceutically acceptable formulations. Claim 5 lists:
Claim 6 narrows the list to cream, suspension, and emulsion. Claim 7 narrows the relevant delivery context further by requiring injection into the urinary tract or bladder and limiting the formulation to liquid, emulsion, suspension, or solution. From a patent-scope perspective, these claims were broader than the FDA-approved Botox urinary indications. The approved clinical product is administered by injection after reconstitution, with cystoscopic delivery to the bladder or detrusor muscle. Oral, topical, rectal, and other listed formulations were not central to the approved Botox urinary-treatment market. The formulation claims also raise technical enablement questions. A patent that lists multiple dosage forms must provide sufficient teaching for the claimed botulinum toxin to remain stable, potent, and therapeutically usable in each relevant formulation. The commercial importance of claims 5 and 6 was therefore lower than that of the intravesical or intradetrusor method claims. How does Patent 7,001,602 compare with FDA-approved botulinum-toxin competitors?Patent 7,001,602 was product-agnostic. It did not claim Botox by trademark. It broadly referred to botulinum toxin and separately identified type A. The principal commercial botulinum-toxin products include Botox, Dysport, Xeomin, Jeuveau, and Daxxify. Their FDA-approved indications, formulations, potency units, manufacturing processes, and clinical data are not interchangeable.
The expired patent did not give Botox permanent product exclusivity. Competitive differentiation now depends on FDA labeling, clinical evidence, dosing convenience, duration, adverse-event profile, supply reliability, physician familiarity, and payer treatment policies. What patent litigation affected Patent 7,001,602?Patent 7,001,602 may have been relevant to historical enforcement of Allergan’s botulinum-toxin platform, but it does not create an active litigation risk today because the patent term has expired. No current market-entry strategy should treat the patent as an enforceable exclusion right. The principal present litigation risks for botulinum-toxin urinary therapy are more likely to involve:
A competitor entering the urinary-incontinence market should assess the surviving patent portfolios of the relevant product sponsors rather than relying on the status of Patent 7,001,602 alone. Which companies challenge Botox urinary-incontinence exclusivity?No company needs to challenge Patent 7,001,602 because the patent has expired. Competitive pressure instead comes from alternative treatments and botulinum-toxin platforms. The competitive landscape includes:
The largest commercial constraint is regulatory differentiation. A rival product cannot simply rely on Patent 7,001,602’s expired claims to obtain a urinary indication. It must establish safety, efficacy, potency, manufacturing consistency, and labeling through the applicable FDA pathway. What is the revenue exposure from Patent 7,001,602?AbbVie does not publicly disclose Botox revenue specifically attributable to urinary incontinence. Public reporting aggregates Botox Cosmetic and therapeutic sales or reports therapeutic Botox at a level that does not isolate overactive bladder and neurogenic detrusor overactivity. As a result, no defensible public revenue figure can be assigned solely to the patent. The commercial exposure is best analyzed through the broader Botox therapeutic franchise, not through a patent-specific royalty or product segment. The patent’s economic value was greatest before expiration, when it supported exclusivity around a clinically important use of botulinum toxin. Its current value is historical and strategic. It helped establish an early intellectual-property position, but it no longer supports a royalty-bearing monopoly or blocks competing clinical practice. How strong is the remaining patent estate for Botox urinary treatment?The strength of Patent 7,001,602 itself is zero as a current exclusion right because the patent is expired. The broader Botox estate may still include later patents concerning:
Those later rights must be assessed patent by patent. An expired foundational method patent does not imply that every later patent covering Botox urinary therapy has also expired. Geographic coverageUS 7,001,602 provided U.S. rights only. Foreign family members, if any, required separate national validation and had separate expiration dates, prosecution histories, claim scopes, and litigation records. A company assessing global launch risk must review European, Canadian, Australian, Japanese, and other national family members independently. What generic or biosimilar launch risks exist?There is no conventional generic launch pathway for Botox based on Patent 7,001,602. Botox is a complex biologic, and a follow-on product must address:
The expired patent removes one legal barrier but does not eliminate development or regulatory barriers. A follow-on manufacturer would also need to avoid surviving patents covering production, formulation, dosing, or delivery. Key Takeaways
FAQsIs Patent 7,001,602 still enforceable against Botox competitors?No. The patent’s U.S. term has expired, so it no longer provides an enforceable exclusion right against competitors practicing the claimed methods. Does the patent cover Botox by name?No. The claims cover botulinum toxin generally and botulinum toxin type A in certain claims. They do not claim the Botox trademark. Does an expired patent permit approval of a competing bladder botulinum toxin?No. Patent expiration removes a patent barrier but does not substitute for FDA approval, biologic manufacturing validation, clinical evidence, or compliant labeling. Are urinary-incontinence uses of Dysport or Xeomin automatically covered by the patent?The patent’s claims were product-neutral enough to potentially encompass administration of other botulinum toxins during the patent term, subject to claim construction and infringement proof. Because the patent is expired, it no longer blocks those uses. Does Patent 7,001,602 cover bladder injections only?No. Claim 7 specifically addresses injection into the urinary tract or bladder, but claim 1 is broader and does not expressly require a particular injection site. References
More… ↓ |
Details for Patent 7,001,602
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Abbvie Inc. | BOTOX COSMETIC | onabotulinumtoxina | For Injection | 103000 | 9-Dec-91 | 7,001,602 | 2023-10-14 |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | 9-Dec-91 | 7,001,602 | 2023-10-14 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,001,602
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9903483 | ⤷ Start Trial |
| United States of America | 2002025327 | ⤷ Start Trial |
| United States of America | 2004126380 | ⤷ Start Trial |
| United States of America | 2004180065 | ⤷ Start Trial |
| United States of America | 2004259788 | ⤷ Start Trial |
| United States of America | 2005048084 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
